<DOC>
	<DOCNO>NCT01560312</DOCNO>
	<brief_summary>Open , multicenter , randomize study enrol patient 3 site Czech Republic . Patients refractory hypertension randomize 1:1 manner either renal denervation plus optimal medical antihypertensive treatment without spironolactone antihypertensive treatment alone include spironolactone contraindicate . The primary end-point change Systolic Diastolic Blood Pressure ( BP ) baseline 1 year randomization evaluate 24-hours BP monitoring . Expected enrollment 120 patient . Patients follow-up plan 3 year .</brief_summary>
	<brief_title>Renal Denervation Refractory Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Refractory hypertension office SBP &gt; 140 mmHg SBP &gt; 130 24hours Holter blood pressure monitor Treatment least 3 antihypertensive medication include diuretic optimal dos Age &gt; 18 year Signed informed consent Secondary form hypertension Chronic renal disease ( serum creatinine &gt; 200 umol/l ) Pregnancy History myocardial infarction stroke last 6 month Severe valvular stenotic disease Anatomic abnormalities variant renal artery include aneurysm , severe stenosis , reference diameter &lt; 4 mm length &lt; 20 mm Increased bleed risk ( thrombocytopenia &lt; 50 , INR &gt; 1.5 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Renal denervation</keyword>
	<keyword>Resistant hypertension</keyword>
	<keyword>Spironolactone</keyword>
	<keyword>Long-term Outcome</keyword>
</DOC>